Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.57 USD

38.57
547,082

+0.11 (0.29%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt

by Zacks Equity Research

Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.

5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

by Zacks Equity Research

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

Community Health (CYH) Boosts Obstetrics Care With Technology

by Zacks Equity Research

Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.

Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues

by Zacks Equity Research

Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.

Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.

    Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More

    by Zacks Equity Research

    Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.

    Halozyme (HALO) to Acquire Antares for Auto Injector Platform

    by Zacks Equity Research

    Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

    M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

    by Zacks Equity Research

    We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

    Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

    by Zacks Equity Research

    Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

    Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma

    by Zacks Equity Research

    Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.

    Halozyme Therapeutics (HALO) Up 11.4% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

    by Zacks Equity Research

    argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

    Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

    by Zacks Equity Research

    Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

    Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    New Strong Sell Stocks for January 13th

    by Zacks Equity Research

    CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.

    Halozyme Therapeutics (HALO) Down 19.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance

    by Zacks Equity Research

    Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.

    Halozyme Therapeutics (HALO) Q3 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 30.95% and 13.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Should You Buy Halozyme (HALO) Ahead of Earnings?

    by Zacks Equity Research

    Halozyme (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Is a Beat in Store for Generac (GNRC) This Earnings Season?

    by Zacks Equity Research

    Generac's (GNRC) third-quarter 2021 earnings are likely to have been driven by a solid demand environment and effective acquisition strategies supported by a resilient business model.